|Bid||179.30 x 400|
|Ask||179.39 x 300|
|Day's Range||178.05 - 180.91|
|52 Week Range||161.09 - 209.22|
|PE Ratio (TTM)||184.14|
|Dividend & Yield||0.91 (0.49%)|
|1y Target Est||242.49|
BioCryst's oral hereditary angioedema drug candidate hit the mark in a second interim analysis.
LEXINGTON, Massachusetts, May 25, 2017 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will participate at the Jefferies Healthcare Conference ...
The FDA has accepted Ultragenyx Pharmaceutical Inc. (RARE)'s BLA for rhGUS on a priority review basis and set a PDUFA action date of Nov 16, 2017.